Blog
Common Rule Exceptions to the Use of a Single IRB for Multi-site Research Ends After May 11, 2023
On October 8, 2020, Office for Human Research Protections (OHRP), on behalf of the Department of Health and Human Services (DHHS), issued an exception determination as permitted by 45 CFR 46.114(b)(2)(ii) stating that certain categories of cooperative research...
Pearl IRB 2022 Year-End Schedule
Full board meetings occur Monday afternoons at 4:30 PM Eastern. Complete study submissions received by the EOB Monday, will be reviewed at the Monday meeting of the following week. To ensure a timely review of your study, please refer to the Additional Information...
Harmonization of FDA Regulations with the Common Rule
The 21st Century Cures Act mandated that the Department of Health and Human Services (“DHHS”) “revise the DHHS Human Subject Regulations, the FDA Human Subject Regulations, and the vulnerable populations rules to reduce regulatory duplication and unnecessary delays;...
Ask the Expert: How to Ensure Your Submission Package is Ready for IRB Review
This is the fourth of our “Ask the Expert” blogs, a series featuring the wisdom and seasoned insight of Pearl Pathways Advisors and Consultant Advisors. Gretchen Parker, PhD, RAC, CIP, Pearl’s IRB Co-Chair, Senior Advisor, was interviewed for this piece. If you have...
Fast Tracking IRB Approval Takes Skill and Strategy
In clinical research, the purpose of institutional review board (IRB) review is to ensure the rights and welfare of human subjects are protected. Unnecessary delays in the IRB review process can prevent treatments from getting to patients and slow the improvement of...